Drugs / HW091077
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07483489 | May 2026 → Aug 2028 expected | respiratory system disorder | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HW091077 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483489 ↗ |
| Route | Oral | “HW091077 oral tablet, oral, QD” NCT07483489 ↗ |